Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Iron Mountain Inc (IRM) vs GeneDx Holdings Corp (WGS) Price & Performance

Iron Mountain IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Iron Mountain Inc vs GeneDx Holdings Corp — how do they compare? Iron Mountain Inc trades at $124.72 (market cap $36.96B), while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: Iron Mountain Inc is far larger — about 20.5× GeneDx Holdings Corp's market cap, and Iron Mountain Inc pays a 2.78% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

IRMWGS
Market Cap
$36.96B$1.80B
Sector
Real EstateTechnology
52-Week High
$133.06$167.51
52-Week Low
$78.86$34.51
Enterprise Value
$56.10B$1.80B
Dividend Yield
2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Iron Mountain Inc

Iron Mountain (IRM) trades at $124.38, up 0.45% for the day, with a bullish technical signal and strong recent earnings beats. The stock has rallied 30.2% over three months, supported by data center growth and recurring storage revenue. However, the company faces high debt levels, with a debt-to-asset ratio of 74.39% in 2024, and a P/E ratio of 134.59 suggests elevated valuation. Analyst consensus is bullish with a $138.67 price target, though the RSI_6 at 84.86 indicates potential overbought conditions near-term.

Outlook remains positive due to consistent earnings outperformance and data center expansion, but risks include significant leverage and declining paper storage demand. The stock offers a dividend yield with a recent $0.86 payment, yet investors should weigh high valuation multiples against growth prospects in a competitive information services sector.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.

Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.

Returns comparison

Trailing returns across standard periods

About Iron Mountain Inc

Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business

Read more on IRM

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS